P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.

P21-activated kinase 1 (PAK1) as a therapeutic target in BRAF wild-type melanoma.

BACKGROUND: Although remarkable clinical response rates in melanoma have been observed using vemurafenib or dabrafenib in patients with tumors carrying oncogenic mutations in BRAF, a substantial unmet medical need remains for the subset of patients with wild-type BRAF tumors. METHODS: To investigate...

Full description

Bibliographic Details
Main Authors: Ong, C, Jubb, A, Jakubiak, D, Zhou, W, Rudolph, J, Haverty, P, Kowanetz, M, Yan, Y, Tremayne, J, Lisle, R, Harris, A, Friedman, L, Belvin, M, Middleton, M, Blackwood, E, Koeppen, H, Hoeflich, K
Format: Journal article
Language:English
Published: 2013

Similar Items